194 related articles for article (PubMed ID: 8553032)
1. [Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease].
Netzer P
Schweiz Med Wochenschr; 1995 Dec; 125(50):2438-42. PubMed ID: 8553032
[TBL] [Abstract][Full Text] [Related]
2. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
[TBL] [Abstract][Full Text] [Related]
3. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
[TBL] [Abstract][Full Text] [Related]
4. [Pentasa (mesalazine) and pregnancy].
Jonville-Bera AP; Soyez C; Fignon A; Moraine C; Berger C; Autret E
Therapie; 1994; 49(5):443-5. PubMed ID: 7855761
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
6. [Mesalazine].
Netzer P
Dtsch Med Wochenschr; 1996 Jan; 121(1-2):42. PubMed ID: 8565806
[No Abstract] [Full Text] [Related]
7. [Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease].
García-Díaz M; Nevado L; Berenguer A; Bureo JC; Bureo P; Sáenz de Santamaría J
Gastroenterol Hepatol; 1995 Jan; 18(1):18-21. PubMed ID: 7621266
[TBL] [Abstract][Full Text] [Related]
8. [Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine].
Glintborg B
Ugeskr Laeger; 2000 Aug; 162(34):4553-4. PubMed ID: 10981226
[TBL] [Abstract][Full Text] [Related]
9. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
10. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
Uittenbogaart SB; Klemt-Kropp M
Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
[TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.
Steinhart AH; Hemphill D; Greenberg GR
Am J Gastroenterol; 1994 Dec; 89(12):2116-24. PubMed ID: 7977225
[TBL] [Abstract][Full Text] [Related]
12. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
13. [Crohn disease: prevention and drug therapy].
Gross V; Andus T; Schölmerich J
Chirurg; 1995 Aug; 66(8):757-63. PubMed ID: 7587538
[TBL] [Abstract][Full Text] [Related]
14. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine-induced lupus.
Timsit MA; Anglicheau D; Lioté F; Marteau P; Dryll A
Rev Rhum Engl Ed; 1997 Oct; 64(10):586-8. PubMed ID: 9385697
[TBL] [Abstract][Full Text] [Related]
17. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
18. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
19. Review article: chronic active disease and maintaining remission in Crohn's disease.
Kamm MA
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
[TBL] [Abstract][Full Text] [Related]
20. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease.
Calviño J; Romero R; Pintos E; Losada E; Novoa D; Güimil D; Mardaras J; Sanchez-Guisande D
Clin Nephrol; 1998 Apr; 49(4):265-7. PubMed ID: 9582560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
